Erturk Ismail, Karadurmus Nuri, Kızıloz Halil, Acar Ramazan, Yildiz Birol, Aykan Musa Baris, Esen Ramazan, Buyukturan Galip, Urun Yuksel, Erdem Gokhan, Arpacı Fikret
Department of Medical Oncology, Gulhane School of Medicine, University of Health Sciences, Ankara, Turkey.
Department of Urology, Nevsehir Government Hospital, Nevsehir, Turkey.
J Oncol Pharm Pract. 2021 Oct;27(7):1657-1664. doi: 10.1177/1078155220964540. Epub 2020 Oct 13.
To demonstrate the real-life data about patients who underwent AHSCT due to GCT.
Between November 2016 and April 2020, 64 patients who received CE as high-dose chemotherapy for AHSCT in the Gulhane Education and Research Hospital were included in the study. Sixty-one patients received one AHSCT with CE chemotherapy regimen. Survival data and clinical characteristics were evaluated retrospectively.
The mean age of the patients were 31.9 ± 9 (min-max:18-55). With a median follow-up of 10.7 ± 8.7 months, the 1-year progression-free survival (PFS) rate was 57.8%, and the 1-year overall survival rate was 77.5%. Median overall survival (OS) and progression-free survival (PFS) times were 21.5 ± 1.8 (95% CI: 14.5-33.4) and 20 ± 2 months, respectively. The response rate was 72%. There were three treatment-related deaths.
This sizeable single-centre study shows that patients with relapsed metastatic GCT are curable by CE as high dose chemotherapy plus AHSCT with reliable toxicity even for a single cycle.
展示因生殖细胞肿瘤（GCT）接受自体造血干细胞移植（AHSCT）患者的真实数据。
2016年11月至2020年4月期间，在古勒汗教育与研究医院接受环磷酰胺（CE）作为AHSCT大剂量化疗的64例患者纳入本研究。61例患者接受了一次采用CE化疗方案的AHSCT。对生存数据和临床特征进行回顾性评估。
患者的平均年龄为31.9±9岁（最小-最大：18-55岁）。中位随访时间为10.7±8.7个月，1年无进展生存率（PFS）为57.8%，1年总生存率为77.5%。中位总生存期（OS）和无进展生存期（PFS）分别为21.5±1.8（95%CI：14.5-33.4）个月和20±2个月。缓解率为72%。有3例与治疗相关的死亡。
这项规模较大的单中心研究表明，复发转移性GCT患者即使仅接受一个周期的CE大剂量化疗加AHSCT，也可治愈，且毒性可靠。
